Physician profile
Gia L Landry
NPI 1053467365
$511,025.79
in general payments reported to CMS, 2019-2025
25 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $13K · 2021: $47K · 2022: $43K · 2023: $82K · 2024: $140K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $279K · Travel and Lodging: $52K · Consulting Fee: $37K · Food and Beverage: $10K · Honoraria: $5,348 · Education: $52.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,174.50 |
| Travel and Lodging | $52,018.30 |
| Consulting Fee | $36,910.00 |
| Food and Beverage | $10,464.66 |
| Honoraria | $5,347.50 |
| Education | $52.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $382,873.89 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Madrigal Pharmaceuticals | $111,124.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Fujifilm Healthcare Americas Corporation | $7,858.55 | 2023-2024 | Utaswako Afp-L3 |
| Ipsen Biopharmaceuticals, INC | $6,614.85 | 2024-2025 | Iqirvo |
| Abbvie INC. | $523.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.52 | 2019-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $269.01 | 2019-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $216.15 | 2023-2024 | Terlivaz |
| Ardelyx, INC. | $210.18 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $188.69 | 2024-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $101.74 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Qol Medical, LLC | $97.21 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $96.37 | 2025 | Voquezna |
| Genzyme Corporation | $86.45 | 2025 | |
| Novo Nordisk INC | $82.76 | 2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.88 | 2019 | |
| Shionogi INC | $54.59 | 2019 | |
| Glaxosmithkline, LLC. | $50.15 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $37.81 | 2025 | Dupixent |
| Orphalan INC | $23.58 | 2024 | Cuvrior |
| Aimmune Therapeutics, INC. | $22.56 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $18.44 | 2025 | Suflave, Sutab |
| Exact Sciences Corporation | $17.41 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $16.89 | 2025 | |
| Dynavax Technologies Corporation | $14.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gia Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.